The use of a mAb that neutralizes the three isoforms of TGF-β (clone 1D11) in combination with a vaccine targeting glioma-associated antigen-derived CD8 T cells resulted in synergistic expansion of antigen-specific T cells and prolonged survival of tumor-bearing mice [26]. The gene discussed is CD8A; the disease is neoplasm.